Taiwan · Delayed Price · Currency is TWD Yoda Pharmaceuticals Statistics
Total Valuation
TPEX:7829 has a market cap or net worth of TWD 4.64 billion. The enterprise value is 4.19 billion.
| Market Cap | 4.64B |
| Enterprise Value | 4.19B |
Important Dates
The next estimated earnings date is Thursday, November 27, 2025.
| Earnings Date | Nov 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:7829 has 79.39 million shares outstanding. The number of shares has increased by 522.45% in one year.
| Current Share Class | 79.39M |
| Shares Outstanding | 79.39M |
| Shares Change (YoY) | +522.45% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 16.96% |
| Owned by Institutions (%) | 0.00% |
| Float | 57.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 10.44 |
| P/TBV Ratio | 10.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.26 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.72 |
Financial Position
The company has a current ratio of 15.97, with a Debt / Equity ratio of 0.00.
| Current Ratio | 15.97 |
| Quick Ratio | 15.66 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -17,989.19 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -64.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 59.62 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 43.99 |
| Average Volume (20 Days) | 142,537 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -287.83M |
| Pretax Income | -315.73M |
| Net Income | -315.73M |
| EBITDA | -286.28M |
| EBIT | -287.83M |
| Earnings Per Share (EPS) | -4.35 |
Balance Sheet
The company has 449.92 million in cash and 1.21 million in debt, giving a net cash position of 448.71 million or 5.65 per share.
| Cash & Cash Equivalents | 449.92M |
| Total Debt | 1.21M |
| Net Cash | 448.71M |
| Net Cash Per Share | 5.65 |
| Equity (Book Value) | 443.97M |
| Book Value Per Share | 5.59 |
| Working Capital | 431.73M |
Cash Flow
In the last 12 months, operating cash flow was -282.79 million and capital expenditures -1.76 million, giving a free cash flow of -284.55 million.
| Operating Cash Flow | -282.79M |
| Capital Expenditures | -1.76M |
| Free Cash Flow | -284.55M |
| FCF Per Share | -3.58 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TPEX:7829 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -522.45% |
| Shareholder Yield | -522.45% |
| Earnings Yield | -6.81% |
| FCF Yield | -6.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |